For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 275 | 4,048 | ||
| General and administrative | 213 | 514 | ||
| Total operating expenses | 488 | 4,562 | ||
| Net operating loss | -488 | -4,562 | ||
| Change in fair value of warrant and derivative liabilities | -315 | - | ||
| Loss on convertible debt conversions | -43 | - | ||
| Interest expense | 130 | 35 | ||
| Total other income (expense) | -488 | -35 | ||
| Net loss | -976 | -4,597 | ||
| Basic EPS | - | -0.55 | ||
| Diluted EPS | -0.11 | -0.55 | ||
| Basic Average Shares | - | 8,308,000 | ||
| Diluted Average Shares | 8,521,000 | 8,308,000 | ||
BIO-PATH HOLDINGS, INC. (BPTH)
BIO-PATH HOLDINGS, INC. (BPTH)